ALPS Advisors’s Kyntra Bio KYNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-2,476
| Closed | -$1.16M | – | 1013 |
|
|
2023
Q1 | $1.16M | Sell |
2,476
-72
| -3% | -$38.1K | 0.01% | 432 |
|
|
2022
Q4 | $1.02M | Buy |
2,548
+500
| +24% | +$192K | 0.01% | 476 |
|
|
2022
Q3 | $666K | Sell |
2,048
-166
| -7% | -$53.5K | 0.01% | 549 |
|
|
2022
Q2 | $585K | Sell |
2,214
-1,609
| -42% | -$411K | 0.01% | 555 |
|
|
2022
Q1 | $1.15M | Sell |
3,823
-469
| -11% | -$163K | 0.01% | 298 |
|
|
2021
Q4 | $1.51M | Sell |
4,292
-249
| -5% | -$77.5K | 0.02% | 318 |
|
|
2021
Q3 | $1.16M | Sell |
4,541
-293
| -6% | -$104K | 0.01% | 375 |
|
|
2021
Q2 | $3.22M | Sell |
4,834
-1,792
| -27% | -$1.03M | 0.03% | 210 |
|
|
2021
Q1 | $5.75M | Buy |
6,626
+93
| +1% | +$99K | 0.06% | 171 |
|
|
2020
Q4 | $6.06M | Buy |
6,533
+1,924
| +42% | +$2.02M | 0.07% | 166 |
|
|
2020
Q3 | $4.74M | Sell |
4,609
-253
| -5% | -$272K | 0.07% | 164 |
|
|
2020
Q2 | $4.93M | Sell |
4,862
-1,465
| -23% | -$1.36M | 0.07% | 153 |
|
|
2020
Q1 | $5.5M | Sell |
6,327
-702
| -10% | -$698K | 0.09% | 140 |
|
|
2019
Q4 | $7.54M | Buy |
7,029
+96
| +1% | +$98K | 0.06% | 132 |
|
|
2019
Q3 | $6.41M | Sell |
6,933
-256
| -4% | -$281K | 0.05% | 131 |
|
|
2019
Q2 | $8.12M | Buy |
7,189
+1,030
| +17% | +$1.13M | 0.06% | 125 |
|
|
2019
Q1 | $8.37M | Sell |
6,159
-1,697
| -22% | -$2.3M | 0.06% | 130 |
|
|
2018
Q4 | $9.09M | Buy |
7,856
+1,887
| +32% | +$2.12M | 0.07% | 119 |
|
|
2018
Q3 | $9.07M | Buy |
5,969
+1,142
| +24% | +$1.76M | 0.06% | 125 |
|
|
2018
Q2 | $7.55M | Buy |
4,827
+427
| +10% | +$557K | 0.05% | 132 |
|
|
2018
Q1 | $5.08M | Buy |
4,400
+765
| +21% | +$1.01M | 0.04% | 146 |
|
|
2017
Q4 | $4.31M | Buy |
3,635
+515
| +17% | +$646K | 0.03% | 147 |
|
|
2017
Q3 | $4.2M | Buy |
3,120
+595
| +24% | +$627K | 0.03% | 149 |
|
|
2017
Q2 | $2.04M | Buy |
2,525
+352
| +16% | +$245K | 0.01% | 185 |
|
|
2017
Q1 | $1.34M | Sell |
2,173
-255
| -11% | -$155K | 0.01% | 196 |
|
|
2016
Q4 | $1.3M | Sell |
2,428
-774
| -24% | -$386K | 0.01% | 199 |
|
|
2016
Q3 | $1.66M | Sell |
3,202
-307
| -9% | -$145K | 0.01% | 195 |
|
|
2016
Q2 | $1.44M | Buy |
3,509
+750
| +27% | +$343K | 0.01% | 193 |
|
|
2016
Q1 | $1.47M | Sell |
2,759
-473
| -15% | -$236K | 0.02% | 169 |
|
|
2015
Q4 | $2.46M | Sell |
3,232
-479
| -13% | -$318K | 0.02% | 161 |
|
|
2015
Q3 | $20.3K | Buy |
3,711
+1,357
| +58% | +$822K | 0.02% | 170 |
|
|
2015
Q2 | $1.38M | Buy |
+2,354
| New | +$1.37M | 0.01% | 190 |
|
Other funds holding KYNB
AC
ALPS Advisors's KYNB Position: Q2 2023 in Review
ALPS Advisors sold out of Kyntra Bio (KYNB) in Q2 2023, closing a stake of 2,476 shares — an estimated $1.16M sold.
ALPS Advisors first reported a position in KYNB in Q2 2015 and held it in 32 quarters. The position peaked at $9.09M in Q4 2018. 152 funds tracked by Wall St. Rank hold KYNB as of Q2 2023.
- ALPS Advisors reported no remaining Kyntra Bio position as of Q2 2023 after selling out during the quarter.
- ALPS Advisors sold 2,476 Kyntra Bio shares in Q2 2023, an estimated $1.16M.
- ALPS Advisors first reported a position in Kyntra Bio in Q2 2015 and held it in 32 quarters.
- ALPS Advisors's Kyntra Bio position peaked at $9.09M in Q4 2018.
- 152 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2023.
Based on ALPS Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.